Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T16:11:50.470Z.
Calculation as of: 2026-10-06T16:11:50.470Z.
Quote observation: 2026-10-06T16:09:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2576380beaab4b3cbce085b4235445012990db653f345db98d0cfe80ba67c11f
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$51.28M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Dogwood Therapeutics, Inc. (DWTX) | $52.46M | N/A | N/A | N/A | N/A |
| NOMAD Power Solutions, Inc. (NMAD)vs › | $52.47M | N/A | N/A | N/A | N/A |
| ImageneBio Inc (IMA)vs › | $53.01M | N/A | N/A | N/A | N/A |
| biote Corp. (BTMD)vs › | $52.48M | 10.94% | 20.03% | 16.76% | 21.84% |
| Clene Inc. (CLNN)vs › | $51.50M | N/A | N/A | N/A | N/A |
| eXoZymes, Inc. (EXOZ)vs › | $51.42M | N/A | N/A | N/A | N/A |
| Rani Therapeutics Holdings, Inc. (RANI)vs › | $51.28M | N/A | N/A | N/A | N/A |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $51.13M | N/A | N/A | N/A | N/A |
| INmune Bio, Inc. (INMB)vs › | $50.78M | N/A | 3.11% | 2.71% | 2.71% |
| Envoy Medical, Inc. (COCH)vs › | $51.34M | N/A | 0.59% | 0.59% | 0.59% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
